Reassortant Avian Influenza Virus (H5 Subtype) Bivalent Vaccine, Inactivated
- H5N6(2.3.4.4b and 2.3.4.4h); H5N1(2.3.4.4b); H5N1(2.3.2.1c); H5N1(2.2.1); H5(2.3.4.4c)
- Indication / Application: Used for preventing Avian Influenza in chickens caused by Avian Influenza viruses of two clades： H5 subtype 2.3.4.4b and 2.3.4.4h
- Manufacturing: Produced in GMP-certified facility
- Supply Mode: Bulk Supply / Distributor / OEM Available
- Origin: China
Generic Name
Reassortant Avian Influenza Virus Bivalent Vaccine, Inactivated (Subtype H5)
Composition and Content
| Disease | Strain | Antigen Content | Optional Strain(s) |
|---|---|---|---|
| AI(H5) | H5N6 (2.3.4.4h) | ≥ 108.5 EID50/0.1ml |
H5N6 (2.3.4.4b and 2.3.4.4h); H5N1 (2.3.4.4b); H5N1 (2.3.2.1c); H5N1 (2.2.1); H5 (2.3.4.4c) |
| H5N8 (2.3.4.4b) | ≥ 108.5 EID50/0.1ml |
Indications
For the prevention of avian influenza caused by H5N6 subtype clade 2.3.4.4h and H5N8 subtype clade 2.3.4.4b viruses.
Dosage and Administration
Administer intramuscularly in the breast or subcutaneously in the neck.
Chickens 21 days of age or younger: 0.3 mL per dose, providing 4 months of immunity; chickens over 21 days of age: 0.5 mL per dose, providing 6 months of immunity.
Adverse Reactions
Generally, no adverse reactions occur.
Specification
250 mL/bottle; 500 mL/bottle.
Storage and Shelf Life
Store at 2-8°C. Shelf life: 24 months.
Appearance
A uniform milky-white emulsion.
Precautions
- 1. For vaccination of healthy chickens only.
- 2. Inspect before use. Do not use if discoloration, emulsion separation, leakage, foreign-matter contamination, or any other abnormality is observed.
- 3. Allow the vaccine to reach room temperature and shake thoroughly before use.
- 4. Use the vaccine on the day the vial is opened.
- 5. Do not freeze or expose the vaccine to high temperatures during transport or use.
- 6. Dispose of used vaccine vials, remaining vaccine, and syringes safely.
- 7. Do not use within 28 days before slaughter.
1. Dual-Strain Broad Protection
Bivalent design targeting H5N8 (2.3.4.6 clade, R2346) and H5N1 (2.3.2.1v clade, R232V)—covers ≥90% of circulating H5 variants ,cross-protecting heterologous subclades.
2. Fast, Long-Lasting Immunity
- The vaccine contains inactivated recombinant Avian Influenza viruses, comprising the H5N8 subtype strain R2346 and the H5N1 subtype strain R232V. The content of both antigens before inactivation was ≥ 1×108.5EID50/0.1 ml.
- Durable protection: Immunity lasts ≥6 months in breeders/layers; maternal antibodies protect chicks for 3–4 weeks post-hatch.
- Field-proven RPS: 95–100% protection in chickens, 90–95% in ducks .
3. Exceptional Safety & Compatibility
- Non-pathogenic: Fully attenuated (ICPI=0, MDT>140h); no reversion to virulence risk.
- Low reactogenicity: <5% of birds show mild, transient local swelling/fever—no impact on growth or egg production.
- Co-administrable: Works with NDV/IBV vaccines (no immune interference).
- Residue-free: Compliant with EU/FDA food safety rules.
4. Advanced Manufacturing & Stability
- Cell culture (Vero cell) production: Scalable , no egg-borne contaminants.
- Novel adjuvant: Boosts both humoral (IgY) and cellular immunity for stronger protection.
- Due to significant variations in the prevalent H5 avian influenza strains across different regions, we can adjust the H5 avian influenza antigen combinations according to customer requirements to achieve optimal disease prevention effects.
- Clades:H5 subtype 2.3.2.1b/2.3.2.1e/2.3.4.4b/2.3.4.4c/2.3.4.4e/2.3.4.4h